Second- or third-line nivolumab (Nivo) versus nivo plus ipilimumab (Ipi) in malignant pleural mesothelioma (MPM) patients: Results of the IFCT-1501 MAPS2 randomized phase II trial

A. Scherpereel , J. Mazieres , L. Greillier , P. Dô , O. Bylicki , I. Monnet , R. Corre , C. Audigier-Valette , M. Locatelli-Sanchez , O. Molinier , L. Thiberville (1, 2) , T. Urban , C. Ligeza-Poisson , D. Planchard , E. Amour , F. Morin , D. Moro-Sibilot , G. Zalcman

1 Service de pneumologie, oncologie thoracique et soins intensifs respiratoires [Rouen]
2 QuantIF-LITIS - Equipe Quantification en Imagerie Fonctionnelle

Domaines: Sciences du Vivant [q-bio]

A. Scherpereel, J. Mazieres, L. Greillier, P. Dô, O. Bylicki, et al.. Second- or third-line nivolumab (Nivo) versus nivo plus ipilimumab (Ipi) in malignant pleural mesothelioma (MPM) patients: Results of the IFCT-1501 MAPS2 randomized phase II trial. Journal of Clinical Oncology, 2017. ⟨hal-01676507⟩